UK Trials New Prostate Cancer Treatment with Reduced Side Effects Potential
A new trial for a prostate cancer treatment is underway in the UK, aimed at reducing side effects associated with traditional surgeries. Supported by the National Institute for Health and Care Research (NIHR), the trial tests the effectiveness of Aquablation. This innovative therapy employs robotics, artificial intelligence, and real-time imaging to treat prostate cancer.
Understanding Traditional Treatments
Currently, prostate cancer is primarily treated with a radical prostatectomy, which involves removing the entire prostate gland. This method is suitable for men whose cancer is localized and carries a significant risk of serious side effects. Men may experience infection, erectile dysfunction, and urinary complications after surgery.
The Aquablation Approach
Aquablation is a less invasive treatment that utilizes a high-pressure water jet for cancerous tissue removal. Surgeons can map the prostate in real time using ultrasound, enabling them to pinpoint and eliminate cancer cells while avoiding critical nerves that control erectile function and bladder health.
Trial Details
This pivotal trial is funded by Procept BioRobotics, a US-based company, and spans across seven countries. Four of its centres are located in the UK:
- Royal Marsden
- Guy’s and St Thomas’ NHS Foundation Trust
- Royal Free London NHS Foundation Trust
- Norfolk and Norwich University Hospitals NHS Foundation Trust
Overall, the trial aims to recruit 280 patients worldwide, focusing on those with early-stage, localized prostate cancer who have opted for surgery.
Expert Insights
Philip Charlesworth, a consultant urological surgeon at the Royal Marsden, emphasized the importance of minimizing side effects. He stated, “This trial is measuring Aquablation therapy, which uses a robotic approach to surgically remove cancer while preserving a man’s ability to remain continent and maintain sexual activity.”
The trial presents a promising alternative surgical treatment option for localized prostate cancer, potentially changing standard care worldwide.
Prostate Cancer Statistics
Current statistics reveal a concerning rise in prostate cancer cases. According to Prostate Cancer UK:
- One in eight men will be diagnosed with prostate cancer in their lifetime.
- A total of 58,218 men were diagnosed in England last year, marking a 9% increase from 2022.
Screening Guidelines and Political Pressure
Recent debates surround prostate cancer screening. Scientific advisers have recommended against routine screening for most men, citing potential risks. However, they have suggested screening for men with BRCA1 and BRCA2 genetic mutations every two years from ages 45 to 61.
Health Secretary Wes Streeting expressed surprise at the recommendation. High-profile figures, including Olympian Sir Chris Hoy and former prime minister Lord Cameron, have called for expanded screening following their own prostate cancer diagnoses.
The Aquablation trial represents a significant step forward in the fight against prostate cancer, with the potential for minimizing side effects and improving the quality of life for patients.
